Monograph Capital
VC Fund
London, United Kingdom
Monograph Capital is a life sciences venture firm. We find and fund groundbreaking life sciences companies to transform promising science into real, life-changing treatments for people across the world.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Monograph Capital invests in
Stages Monograph Capital invests in
Countries Monograph Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles Conn
|
|||
Tim Funnell
|
|||
Bonnie van Wilgenburg
|
|||
Investment Focus
Industry
- Biotechnology 8 (44%)
- Medical 5 (28%)
- Health Care 5 (28%)
- Therapeutics 5 (28%)
- Life Science 4 (22%)
Stage
- Series A 9 (50%)
- Series B 5 (28%)
- Series C 1 (6%)
Country
- United States 7 (39%)
- United Kingdom 5 (28%)
- Canada 1 (6%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Charles Conn
Co-founder
|
Co-founder | Total investments: 0 | Find email | |
|
Tim Funnell
Partner
|
Partner | Total investments: 5 | Find email | |
|
Bonnie van Wilgenburg
Principal
|
Principal | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ollin Biosciences
|
Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M / Series B / Jun 24, 2026 | |
RQ Bio
|
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M / Series A / Jun 24, 2026 | |
Nocion Therapeutics
|
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M / Series B / Jan 07, 2026 | |
ProLynx
|
ProLynx is a biotechnology company that develops proprietary drug-delivery technologies designed to extend the half-life of therapeutic molecules, including peptides, proteins, and small molecules, so they maintain effective levels in the body for controlled periods. The company’s core platform uses β-eliminative linkers that are programmed torelease native drugs from macromolecular carriers (such as circulating polymers or hydrogel microspheres) at predictable rates, enabling sustained release over weeks to months. ProLynx applies this technology to create long-acting therapeutic candidates and partners with pharmaceutical firms and academic researchers to design and test novel drug conjugates. Its pipeline includes extended-duration therapies for metabolic and obesity indications, with a focus on formulations engineered for monthly or quarterly dosing schedules. | $70M / Series A / Dec 11, 2025 | |
Elevara Medicine
|
Elevara Medicines addresses a basic issue in rheumatoid arthritis (RA): individuals who fail to achieve disease remission using immune-targeted therapies. Elevara Medicines intends to breach the efficacy barrier that patients face with current immunosuppressive medications. | $70M / Series A / Oct 22, 2025 | |
|
Ollin Biosciences
|
Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $100M / Series A / Sep 17, 2025 | |
Maxion Therapeutics
|
Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M / Series A / Mar 17, 2025 | |
Ouro Medicines
|
Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline. | $120M / Series A / Jan 10, 2025 | |
Autobahn Therapeutics
|
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’spipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. | $100M / Series C / Jul 24, 2024 | |
|
Nocion Therapeutics
|
Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $62M / Series B / Mar 04, 2024 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Monograph Capital invest in?
Monograph Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Monograph Capital?
Public channels for Monograph Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Monograph Capital?
The team at Monograph Capital includes Charles Conn (Co-founder), Tim Funnell (Partner) and Bonnie van Wilgenburg (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
